BloodSurf 2017: News from the blood-biomaterial frontier

Sotiri, Irini; Robichaud, Matthew; Lee, David; Braune, S.; Gorbet, Maud; Ratner, Buddy D.; Brash, John L.; Latour, Robert A.; Reviakine, Ilya

doi:10.1016/j.actbio.2019.01.032

Cited by 24 publications

(26 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complement C3 is triggered to fragment autocatalytically and produces C3b adsorbate for surface opsonisation; a surface that is now an attractant for inflammatory cells [45]. There is cooperation between the coagulation and complement pathways, and this later leads to the incorporation of inflammatory cells within the developing surface thrombus (Figure 4) [46,47]. The platelet is the specialist player of blood that really drives the development of a surface thrombus and it is later one of its most prominent constituents.…”

Section: Blood Biological Reactivitymentioning

confidence: 99%

Monitoring with In Vivo Electrochemical Sensors: Navigating the Complexities of Blood and Tissue Reactivity

Vadgama

2020

Sensors

View full text Add to dashboard Cite

The disruptive action of an acute or critical illness is frequently manifest through rapid biochemical changes that may require continuous monitoring. Within these changes, resides trend information of predictive value, including responsiveness to therapy. In contrast to physical variables, biochemical parameters monitored on a continuous basis are a largely untapped resource because of the lack of clinically usable monitoring systems. This is despite the huge testing repertoire opening up in recent years in relation to discrete biochemical measurements. Electrochemical sensors offer one of the few routes to obtaining continuous readout and, moreover, as implantable devices information referable to specific tissue locations. This review focuses on new biological insights that have been secured through in vivo electrochemical sensors. In addition, the challenges of operating in a reactive, biological, sample matrix are highlighted. Specific attention is given to the choreographed host rejection response, as evidenced in blood and tissue, and how this limits both sensor life time and reliability of operation. Examples will be based around ion, O2, glucose, and lactate sensors, because of the fundamental importance of this group to acute health care.

show abstract

Section: Blood Biological Reactivitymentioning

confidence: 99%

Monitoring with In Vivo Electrochemical Sensors: Navigating the Complexities of Blood and Tissue Reactivity

Vadgama

2020

Sensors

View full text Add to dashboard Cite

show abstract

“…The available reports, particularly for thrombogenic materials, indicate that albumin and immunoglobulins (IgG) precede the adsorption of fibrinogen and fibronectin, which later can be replaced by high molecular weight kininogen or factor XII . Established methods for studying the composition of adsorbed protein layers are spectroscopic and mass spectrometry‐based techniques such as high resolution tandem or shotgun mass spectrometry (desorption, digestion, and separation of surface adsorbed proteins followed by the identification of the protein fragments via bioinformatics analysis), spectroscopic ellipsometry (dynamic studies of adsorbed layer growth), X‐ray photoelectron spectroscopy (XPS, majorly single component analyses), secondary ion mass spectrometry (SIMS), and time‐of‐flight (ToF)‐SIMS as well as matrix‐assisted laser/desorption/ionization (MALDI) time‐of‐flight mass spectrometry (MALDI‐ToF/MS) . These techniques allow studying protein adsorption on material surfaces, which were contacted with multicomponent or complex solutions, such as blood plasma.…”

Section: Characterization Of the Blood–materials Interactionsmentioning

confidence: 99%

In Vitro Thrombogenicity Testing of Biomaterials

Braune

Latour

Reinthaler

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

reliable, and reproducible. [20][21][22] This is, not least, important for realizing interstudy comparisons of the thrombogenicity of different materials. According, e.g., to the regulation (EU) 2017/745 of the European parliament and of the council on medical devices, in vitro and in vivo tests are a mandatory parts within the preclinical product verification and validation (see Annex II: Technical documentation, 6.1 Preclinical and clinical data). [23] Beyond the results of these tests, also detailed information concerning the test design, respective protocols and data analysis are obligatory to meet the requirements of the regulation, particularly those formulated in the ISO standard 10993 Part 4. [24,25] Since the regulatory agencies provide recommendations rather than protocols or standard operation procedures, accepted standardizations regarding the preanalytical handling of the blood, test conditions, test parameters, reference materials, static or dynamic conditions, flow conditions, and finally, which type of cells and donors should be included is lacking. Also, standard operating procedures how the testing should be performed are lacking. [9] This has led to a situation that laboratories perform in vitro assays under substantially different test conditions, including the preanalytical characterization of blood samples, the application of blood from different species, varying anticoagulation and stabilization or storage times as well as test setups. Taking these variations into account, interlaboratory or interstudy comparisons are impossible. [8,[26][27][28] Here, we review described test methods and procedures for the assessment of the thrombogenicity of materials, prerequisites for a reproducible in vitro testing, applied test system and test parameters for the characterization of the interaction of blood components/cells and the implant. We further review and outline recent approaches that may support realizing reliable, reproducible, and laboratory independent tests.

show abstract

“…Alarmingly, thrombotic and inflammatory complications persist in patients on ACT/APT, while their systemic administration brings the danger of hemorrhagic complications necessitating close patient monitoring. With the prevalence of cardiovascular diseases on the rise and the aging of the population, the problem is only poised to become more severe, and the need for a solution-more acute [2][3][4][5][6].…”

Section: Blood-biomaterials Interactions By Ilya Reviakine and Robert mentioning

confidence: 99%

“…Failure to produce a hemocompatible material for vascular implants, or to offer a reliable protocol for in vitro predictive material hemocompatibility testing, is well-recognized and has been widely discussed in the literature [2][3][4]6]. Over the last several decades, it led to the diminishing interest of clinicians and funding agencies in the material hemocompatibility research.…”

Section: Blood-biomaterials Interactions By Ilya Reviakine and Robert mentioning

confidence: 99%